Wechselwirkungen von Ertapenem

Ertapenem (Invanz), ein Antibiotikum, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 75 dokumentierte Wechselwirkungen: 48 schwerwiegende, 27 mittelschwere, 0 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (48)

  • AmoxicillinPenicillin-AntibiotikumSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Amoxicillin und ClavulansäurePenicillin-AntibiotikumSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • AmpicillinPenicillin-AntibiotikumSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Ampicillin und SulbactamPenicillin-AntibiotikumSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Articain und AdrenalinLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Benzylpenicillin (Penicillin G)Penicillin-AntibiotikumSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • BupivacainLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Bupivacain und AdrenalinLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefaclorCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefadroxilCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefalexinCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefazolinCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefdinirCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefepimCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefiximCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefotaximCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefotetanCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefoxitinCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefpodoximCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefprozilCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CeftarolinCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CeftazidimCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CeftriaxonCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • CefuroximCephalosporinSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • ChloroprocainLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • DesfluranAllgemeinanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • DicloxacillinPenicillin-AntibiotikumSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • EtomidatAllgemeinanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • IsofluranAllgemeinanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • KetaminZNS-dämpfendes ArzneimittelSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • KokainLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • LidocainLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Lidocain und AdrenalinLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Lidocain und PrilocainLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • MepivacainLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • MethohexitalBarbituratSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • NafcillinPenicillin-AntibiotikumSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • OxacillinPenicillin-AntibiotikumSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Phenoxymethylpenicillin (Penicillin V)Penicillin-AntibiotikumSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Piperacillin und TazobactamPenicillin-AntibiotikumSchwerwiegend

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Prilocain und AdrenalinLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • ProbenecidSchwerwiegend

    Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended. (Fachinformation zu Ertapenem, Arzneimittelwechselwirkungen)

  • Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended. (Fachinformation zu Ertapenem, Arzneimittelwechselwirkungen)

  • PropofolZNS-dämpfendes ArzneimittelSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • RopivacainLokalanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • SevofluranAllgemeinanästhetikumSchwerwiegend

    Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (Fachinformation zu Ertapenem, Gegenanzeigen)

  • Valproat-Seminatrium (Divalproex)AntiepileptikumSchwerwiegend

    The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • ValproinsäureAntiepileptikumSchwerwiegend

    The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

Mittelschwere Wechselwirkungen (27)

  • BrivaracetamAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • Cannabidiol (verschreibungspflichtig)AntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • CarbamazepinAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • CenobamatAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • ClobazamBenzodiazepinMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • ClonazepamBenzodiazepinMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • EslicarbazepinAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • EthosuximidAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • FelbamatAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • FosphenytoinAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • GabapentinAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • LacosamidAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • LamotriginAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • LevetiracetamAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • MesuximidAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • OxcarbazepinAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • PerampanelAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • PhenobarbitalBarbituratMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • Phentermin und TopiramatZNS-StimulansMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • PhenytoinAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • PregabalinAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • PrimidonAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • RufinamidAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • TiagabinAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • TopiramatAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • VigabatrinAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

  • ZonisamidAntiepileptikumMittelschwer

    If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (Fachinformation zu Ertapenem, Warnhinweise und Vorsichtsmaßnahmen)

Prüfen Sie Ertapenem gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.